Christina Fregler

Title: Christina Fregler: Innovator in Pharmaceutical Synthesis

Introduction

Christina Fregler is a notable inventor based in Gothenburg, Sweden. She has made significant contributions to the field of pharmaceutical synthesis, particularly in the development of compounds useful for the synthesis of omeprazole. Her work has implications for the pharmaceutical industry, enhancing the purity and efficacy of important medications.

Latest Patents

Christina Fregler holds a patent for "Compounds useful for the synthesis of S- and R-omeprazole and a process for their preparation." This invention relates to an improved method for synthesizing the (S)- or (R)-enantiomer of omeprazole. The process involves oxidizing specific compounds into corresponding sulphoxides, which are then recrystallized to achieve enhanced chemical and optical purity. This method ultimately leads to the production of the desired enantiomers of omeprazole.

Career Highlights

Fregler is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. Her role at AstraZeneca has allowed her to work on innovative projects that push the boundaries of pharmaceutical research and development. With her expertise, she has contributed to advancements that benefit both the industry and patients.

Collaborations

Throughout her career, Christina has collaborated with esteemed colleagues such as Sverker Von Unge and Rolf Bergman. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their respective fields.

Conclusion

Christina Fregler's contributions to pharmaceutical synthesis exemplify the impact of innovative thinking in the medical field. Her patent on the synthesis of omeprazole enantiomers showcases her commitment to enhancing drug purity and efficacy. Through her work at AstraZeneca and collaborations with fellow researchers, she continues to make strides in the world of pharmaceuticals.